| Autor: |
Valle JW; Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie-tr.nwest.nhs.uk, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, Swindell R, Ranson M |
| Jazyk: |
angličtina |
| Zdroj: |
British journal of cancer [Br J Cancer] 2005 Feb 28; Vol. 92 (4), pp. 628-30. |
| DOI: |
10.1038/sj.bjc.6602394 |
| Abstrakt: |
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
